Work

775. Folate Receptor Targeted Virotherapy of Ovarian Cancer Using a Tropism Modified Measles Virus

Year: 2006

Type: article

Abstract: Attenuated measles viruses are being evaluated in a phase I dose escalation trial for ovarian cancer patients. The virus encodes a soluble marker protein to facilitate noninvasive monitoring of viral gene expression. This virus uses either of two measles receptors, CD46 and SLAMV for binding, entry, and subsequent intercellular fusion between infected and uninfected neighboring cells. To minimize potential toxicity due to MV-associated immunosuppression and infection of nontarget tissues, we sought to develop an ovarian cancer exclusive fully retargeted MV.

Source: Molecular Therapy

DOI: 10.1016/j.ymthe.2006.08.861